Last week, Biogen and Applied Genetic Technologies Corp. announced a collaboration and license agreement to develop gene-based therapies for rare genetic disorders of the eye that often lead to blindness.
In the deal, AGTC is eligible to receive over $1 billion, which includes upfront and milestone payments.
Analysts are viewing this deal as validation of gene therapy’s science and potential to become an important driver in the biotech industry in the near future.
According to Oliver Danos, Senior Vice President of Biogen, With this collaboration, Biogen hopes to "advance gene therapies to open possibilities for patients who suffer from diseases that are well understood, but have no adequate treatment.”
Read the Barron's article